EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies

Samir Zaidi, Jooyoung Park iD, Joseph M Chan, Martine P Roudier, Jimmy L Zhao, Anuradha Gopalan, Kristine M Wadosky, Radhika A Patel, Erolcan Sayar iD, Wouter R Karthaus, D Henry Kates, Ojasvi Chaudhary und 22 weitere

Proceedings of the National Academy of Sciences · 09.07.2024 · 121 (28)

DOI: 10.1073/pnas.2322203121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 05.07.2024. Verfasst von Samir Zaidi und 33 weiteren Autor:innen. Beteiligte Einrichtung: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065. Hauptthemen laut MEDLINE: Single-Cell Analysis. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, HHS | NIH | National Cancer Institute (NCI), Howard Hughes Medical Institute (HHMI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules, varies in the process of lineage plasticity, wherein tumor cells alter their identity and acquire new oncogenic properties. A notable example of lineage plasticity is the transformation of prostate adenocarcinoma (PRAD) to neuroendocrine prostate cancer (NEPC)—a growing resistance mechanism that results in the loss of responsiveness to androgen blockade and portends dismal patient survival. To understand how lineage markers vary across the evolution of lineage plasticity in prostate cancer, we applied single-cell analyses to 21 human prostate tumor biopsies and two genetically engineered mouse models, together with tissue microarray analysis on 131 tumor samples. Not only did we observe a higher degree of phenotypic heterogeneity in castrate-resistant PRAD and NEPC than previously anticipated but also found that the expression of molecules targeted therapeutically, namely PSMA , STEAP1 , STEAP2 , TROP2, CEACAM5 , and DLL3 , varied within a subset of gene-regulatory networks (GRNs). We also noted that NEPC and small cell lung cancer subtypes shared a set of GRNs, indicative of conserved biologic pathways that may be exploited therapeutically across tumor types. While this extreme level of transcriptional heterogeneity, particularly in cell surface marker expression, may mitigate the durability of clinical responses to current and future antigen-directed therapies, its delineation may yield signatures for patient selection in clinical trials, potentially across distinct cancer types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Cell AnalysisMaleHumansAnimalsMiceProstatic NeoplasmsAntigens, SurfaceAntigens, NeoplasmBiomarkers, TumorAdenocarcinomaCarcinoma, NeuroendocrineGene Expression Regulation, NeoplasticProstatic Neoplasms, Castration-Resistant

Stichwörter der Autor:innen

cell statesepithelial maliganciesheterogeneitylineage plasticity

Substanzen

Antigens, SurfaceAntigens, NeoplasmBiomarkers, Tumor

Autor:innen und Institutionen

  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • Department of Medicine, Division of Solid Tumor Oncology, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • Department of Biomedical Sciences, Korea University College of Medicine, Seoul 02841, Korea.
  • Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • Department of Urology, University of Washington, Seattle, WA 98195.
  • Astrazeneca Oncology R&D, New York, NY 10016.

ORCID-Profile: Jooyoung Park, Erolcan Sayar, Michael J Morris, Jungmin Choi, Charles L Sawyers

Förderung

  • NCI NIH HHS
  • HHS | NIH | National Cancer Institute (NCI)
  • Howard Hughes Medical Institute (HHMI)

Zitieren

APA

Zaidi, S., Park, J., Chan, J. M., Roudier, M. P., Zhao, J. L., Gopalan, A., Wadosky, K. M., Patel, R. A., Sayar, E., Karthaus, W. R., Kates, D. H., Chaudhary, O., Xu, T., Masilionis, I., Mazutis, L., Chaligné, R., Obradovic, A., Linkov, I., Barlas, A., …, & Sawyers, C. L. (2024). Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies. Proceedings of the National Academy of Sciences, 121(28). https://doi.org/10.1073/pnas.2322203121

Vancouver

Zaidi S, Park J, Chan JM, Roudier MP, Zhao JL, Gopalan A, et al. Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies. Proceedings of the National Academy of Sciences. 2024;121(28). doi:10.1073/pnas.2322203121

BibTeX
@article{Zaidi2024,
  author = {Zaidi, Samir and Park, Jooyoung and Chan, Joseph M and Roudier, Martine P and Zhao, Jimmy L and Gopalan, Anuradha and Wadosky, Kristine M and Patel, Radhika A and Sayar, Erolcan and Karthaus, Wouter R and Kates, D Henry and Chaudhary, Ojasvi and Xu, Tianhao and Masilionis, Ignas and Mazutis, Linas and Chaligné, Ronan and Obradovic, Aleksandar and Linkov, Irina and Barlas, Afsar and Jungbluth, Achim A and Rekhtman, Natasha and Silber, Joachim and Manova-Todorova, Katia and Watson, Philip A and True, Lawrence D and Morrissey, Colm and Scher, Howard I and Rathkopf, Dana E and Morris, Michael J and Goodrich, David W and Choi, Jungmin and Nelson, Peter S and Haffner, Michael C and Sawyers, Charles L},
  title = {Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  volume = {121},
  number = {28},
  doi = {10.1073/pnas.2322203121}
}
Kostenlos starten →